Sensorion SAS

Sensorion SAS

Sensorion SAS

Overview
Date Founded

2009

Headquarters

375, rue du Professeur Joseph Blayac,Montpellier, Occitanie 34080

Type of Company

Public

Employees (Worldwide)

20

Industries

Pharmaceuticals
Biotechnology

Company Description

Sensorion SAS is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo and tinnitus. The company was founded by Christian Chabbert, Gilles Desmadryl, Sylvain Bartolami and Sophie Gaboyard in 2009 and is headquartered in Montpellier, France.

Executives & Employees

Director & Chief Executive Officer

Chief Medical Officer

Chief Business Officer

Head, French Hearing Institute

Director-Clinical Research

Director

Director

Director, Representative of Health Opportunities

Director, Representative of Sofinnova Partners

Director, Representative of Bpifrance Investissement

Board of Directors

Chief Executive Officer & Director at Imvax, Inc.

Director, Representative of Health Opportunities at Sensorion SAS

Operating Partner at Keensight Capital SAS

Managing Director, Public Equity at The Invus Group LLC

Director & Chief Executive Officer at Sensorion SAS

Senior Investment Director at BPIFrance Investissement SAS

Partner at Sofinnova Partners SAS

Investment Manager-Life Sciences at BPIFrance Investissement SAS

Paths to Sensorion SAS
Potential Connections via
Relationship Science
You
Sensorion SAS
Owners & Shareholders
Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Recent Transactions
Details Hidden

Sensorion SAS issued EUR Ordinary Shares

Transaction Advisors
Underwriter

Advised onSensorion SAS issued EUR Ordinary Shares

Sponsor

Advised onSensorion SAS issued EUR Ordinary Shares

Advisors & Consultants
Advisor

Chief Executive Officer at Bionure Farma SL

Advisor

Chief Business Officer at Sensorion SAS

Key Stats and Financials As of 2020
Market Capitalization
$221M
Total Enterprise Value
$7.2M
Earnings Per Share
$-0.13
Three Year Compounded Annual Growth Rate Of Revenue
0%
Revenue
$0
Net Profit
$-10.1M
Total Equity
$65.5M
Investors
Details Hidden

Founder at Sensorion SAS

Details Hidden

Founder at Sensorion SAS

Details Hidden

Co-Founder at Sensorion SAS

Suppliers
Institut Pasteur Investment Services & Portfolio Management | Paris, France

The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris.

INSERM Transfert Initiative SAS Biotechnology | Paris, France

INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages.

Palau Pharma SA Holding Companies | Palau-solità i Plegamans, Spain

Palau Pharma SA is a holding company engaged in the discovery and development of biophamaceuticals for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, neuropathic pain, and chronic obstructive pulmonary disease. The company was founded on March 13, 1991 and is headquartered in Palau Solita i Plegamans, Spain.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Sensorion SAS. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Sensorion SAS's profile does not indicate a business or promotional relationship of any kind between RelSci and Sensorion SAS.